Skip to main content
SpringerLink
Log in

Chronic myelomonocytic leukaemia: diagnosis and therapeutic implications

  • review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Abstract

Chronic myelomonocytic leukaemia (CMML) is a clonal disorder of the haematopoietic stem cell characterised by the presence of an absolute monocytosis in peripheral blood. The disease carries myelodysplastic and myeloproliferative features. This dilemma was sought to be overcome by the World Health Organization (WHO) in 2001, when CMML was classified within a new category of myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN). The identification of molecular markers in patients with CMML has dramatically increased over the past couple of years. However, the impact on prognosis and therapeutic interventions needs to be defined. Testing of new agents in the setting of CMML proves to be difficult due to limited number of patients. This review has a focus on current diagnosis including new molecular data and treatment of CMML.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Vardiman JW, Pierre R, Bain B, Bennett JM, Imbert M, Brunning RD, et al. WHO histological classification of myelodysplastic/myeloproliferative diseases. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours: tumours of the haematopoietic and lympoid tissues. Lyon: International Agency for Research on Cancer (IARC) Press; 2001. pp. 47–59.

  2. Kern W, Bacher U, Haferlach C, Schnittger S, Haferlach T. Acute monoblastic/monocytic leukemia and chronic myelomonocytic leukemia share common immunophenotypic features but differ in the extent of aberrantly expressed antigens and amount of granulocytic cells. Leuk Lymphoma. 2011;52:92–100.

    Article  PubMed  CAS  Google Scholar 

  3. Subira D, Font P, Villalon L, Serrano C, Askari E, Gongora E, et al. Immonophenotype in chronic myelomonocytic leukemia: is it closer to myelodysplastic syndromes or to myeloproliferative disorders? Transl Res. 2008;151:240–5.

    Article  PubMed  CAS  Google Scholar 

  4. Gorczyca W. Flow cytometry immunophenotypic characteristics of monocytic population in acute monocytic leukaemia (AML-M5), acute myelomonocytic leukaemia (AML-M4), and chronic myelomonocytic leukaemia (CMML). Methods Cell Biol. 2004;75:665–7.

    Article  PubMed  Google Scholar 

  5. Xu Y, McKenna RW, Karandikar NJ, Pildain AJ, Kroft SH. Flow cytometric analysis of monocytes as a tool for distinguishing chronic myelomonocytic leukemia from reactive monocytosis. Am J Clin Pathol. 2005;124:799–806.

    Article  PubMed  Google Scholar 

  6. Vardiman JW, Imbert M, Pierre R, Brunning RD, Bain B, Flandrin G, et al. Chronic myelomonocytic leukaemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumors: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. pp. 49–52.

  7. Orazi A, Chiu R, O’Malley DP, Czader M, Allen SL, An C, Vance GH. Chronic myelomonocytic leukemia: the role of bone marrow biopsy immunohistolog. Mod Pathol. 2006;19:1536–45.

    Article  PubMed  CAS  Google Scholar 

  8. Germing U, Gattermann N, Minning H, Heyll A, Aul C. Problems in the classification of CMML-dysplastic versus proliferative type. Leuk Res. 1998;22:871–8.

    Article  PubMed  CAS  Google Scholar 

  9. Fenaux P, Beuscart R, Lai JL, Jouet JP, Bauters F. Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. J Clin Oncol. 1988;6:1417–24.

    PubMed  CAS  Google Scholar 

  10. Storniolo AM, Moloney WC, Rosenthal DS, Cox C, Bennett JM. Chronic myelomonocytic leukemia. Leukemia. 1990;4:766–70.

    PubMed  CAS  Google Scholar 

  11. McClure RF, Dewald GW, Hoyer JK, Hanson CA. Isolated isochromosome 17q: a distinct type of mixed myeloproliferative disorder/myelodysplastic syndrome with an aggressive clinical course. Br J Haematol. 1999;106:445–54.

    Article  PubMed  CAS  Google Scholar 

  12. Burgstaller S, Reiter A, Cross NCP. BCR-ABL negative chronic myeloid leukemia. Curr Hem Malignancy Rep. 2007;2:75–82.

    Article  Google Scholar 

  13. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.

    Article  PubMed  CAS  Google Scholar 

  14. Kosmider O, Gelsi-Bayer V, Ciudad M, Racoeur C, Jooste V, Vey N, et al. TET2 gene mutationis a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica. 2009;94:1676–81.

    Article  PubMed  CAS  Google Scholar 

  15. Kohlmann A, Grossmann V, Klein H, Schindela S, Weiss T, Kazak B, et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol. 2010;28:3858–65.

    Article  PubMed  CAS  Google Scholar 

  16. Dunbar AJ, Gondek LP, O’Keefe CL, Makishima H, Rataul MS, Szpurka H, et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res. 2008;68:10349–57.

    Google Scholar 

  17. Ricci C, Fermo E, Corti S, Molteni M, Faricciotti A, Cortelezzi A, et al. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant. Clin Cancer Res. 2010;16:2246–56.

    Article  PubMed  CAS  Google Scholar 

  18. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zahng L, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106:2162–8.

    Article  PubMed  CAS  Google Scholar 

  19. Pich A, Riera L, Sismondi F, Godio L, Davico Bonino L, Marmont F, Francia di Celle P. JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia. J Clin Pathol. 2009;62:798–801.

    Article  PubMed  CAS  Google Scholar 

  20. Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, McGuire C, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood. 2009;113:6182–92.

    Article  PubMed  CAS  Google Scholar 

  21. Gelsi-Boyer V, Trouplin V, Adelaide J, Aceto N, Remy V, Pinson S, et al. Genome profiling of chronic myelomonoytic leukemia: frequent alterations of RAS and RUNX1 genes. BMC Cancer. 2008;8:299.

    Google Scholar 

  22. Kuo MC, Liang DC, Huang CF, Shih YS, Wu JH, Lin TL, Shih LY. RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. Leukemia. 2009;23:1426–31.

    Article  PubMed  CAS  Google Scholar 

  23. Gelsi-Boyer V, Trouplin V, Adelaide J, Bonansea J, Cervera N, Carbuccia N, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndrome and chronic myelomonocytic leukaemia. Br J Haematol. 2009;145:788–800.

    Article  PubMed  CAS  Google Scholar 

  24. Germing U, Kündgen A, Gattermann N. Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma. 2004;45:1311–8.

    Article  PubMed  CAS  Google Scholar 

  25. Molica S, Iannaccuro P, Albeti A. Chronic myelomonocytic leukemia: a test of a proposed staging system. Am J Haematol. 1990;35:129–30.

    Article  CAS  Google Scholar 

  26. Worsley A, Oscier DG, Stevens J, Darlow S, Figes A, Mufti GJ, Hamblin TJ. Prognostic features of chronic myelomonocytic leukemia: a modified Bournemouth score gives the best prediction of survival. Br J Haematol. 1988;68:17–21.

    Article  PubMed  CAS  Google Scholar 

  27. Aul C, Ganttermann N, Neyll A, Germing U, Gerigs G, Schneider W. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia. 1992;6:52–9.

    PubMed  CAS  Google Scholar 

  28. Gonzales-Medina I, Bueno J, Torrequebrada A, Lopez A, Vallespi T, Massague I. Two groups of chronic myelomonocytic leukemia: myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center. Leuk Res. 2002;26:821–4.

    Article  Google Scholar 

  29. Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood. 2002; 99: 840–9.

    Article  PubMed  CAS  Google Scholar 

  30. Beran M, Wen S, Shen Y, Onida F, Jelinek J, Cortes J, et al. Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognositc Scoring System. Leuk Lymphoma. 2007;48:1150–60.

    Article  PubMed  Google Scholar 

  31. Wattel E, Guerci A, Hecquet B, Economopoulos T, Copplestone A, Mahe B, et al. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Blood. 1996;88:2480–7.

    PubMed  CAS  Google Scholar 

  32. Beran M, Estey E, O’Brien S, Giles FJ, Koller CA, Kornblau S, et al. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk lymphoma. 1998;31:521–31.

    PubMed  CAS  Google Scholar 

  33. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–32.

    Google Scholar 

  34. Wong E, Seymour JF, Kenealy M, Westerman D, Herbert K, Dickinson M. Treatment of chronic myelomonocytic leukemia with azacitidine. Leuk Lymphoma. 2012. Epub ahead of print.

  35. Feldman E, Cortes J, DeAngelo DJ, Holyoake T, Simonsson B, O’Brien SG, et al. On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia. 2008;22:1707–11.

    Article  PubMed  CAS  Google Scholar 

  36. Sliitonen T, Timonen T, Juvonen E, Terävä V, Kutila A, Honkanen T, et al. Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes. Haematologica. 2007;92:1119–22.

    Article  Google Scholar 

  37. Eissa H, Gooley TA, Sorror ML, Nguyen F, Scott BL, Doney K, et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. Biol Blood Marrow Transpl. 2010. doi:10.1016/j.bbmt.2010.09.018.

Download references

Conflict of interest

The author declares that there is no actual or potential conflict of interest in relation to this article.

Author information

Authors and Affiliations

  1. Klinikum Wels-Grieskirchen, Grieskirchnerstr. 42, 4600, Wels, Austria

    Sonja Burgstaller MD

Authors
  1. Sonja Burgstaller MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sonja Burgstaller MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Burgstaller, S. Chronic myelomonocytic leukaemia: diagnosis and therapeutic implications. memo 6, 32–36 (2013). https://doi.org/10.1007/s12254-012-0064-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-012-0064-6

Keywords

Search

Navigation